{"id":117654,"date":"2026-09-04T14:32:21","date_gmt":"2026-09-04T14:32:21","guid":{"rendered":"https:\/\/www.europesays.com\/britain\/117654\/"},"modified":"2026-09-04T14:32:21","modified_gmt":"2026-09-04T14:32:21","slug":"hutchmed-secures-110-million-licensing-deal-with-gsk-for-promising-solid-tumour-drug-etpharma","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/britain\/117654\/","title":{"rendered":"HUTCHMED Secures $110 Million Licensing Deal with GSK for Promising Solid Tumour Drug, ETPharma"},"content":{"rendered":"<p>                                        <img fetchpriority=\"high\" decoding=\"async\" width=\"590\" height=\"442\" class=\"unveil\" loading=\"eager\" style=\"width:100%;max-height:100%\" src=\"https:\/\/www.europesays.com\/britain\/wp-content\/uploads\/2026\/09\/133750147.cms.png\" captionrendered=\"1\" alt=\"\"\/>Shanghai: GSK subsidiary <a id=\"30460470\" type=\"Denny\" weightage=\"20\" keywordseo=\"GlaxoSmithKline\" source=\"keywords\" class=\"news-keywords\" href=\"https:\/\/pharma.economictimes.indiatimes.com\/tag\/glaxosmithkline\" rel=\"nofollow noopener\" target=\"_blank\">GlaxoSmithKline<\/a> Intellectual Property (No. 4) Ltd will pay a unit of HUTCHMED (China) $110 million upfront for rights to an experimental drug for <a id=\"38923533\" type=\"Denny\" weightage=\"20\" keywordseo=\"solid-tumours\" source=\"keywords\" class=\"news-keywords\" href=\"https:\/\/pharma.economictimes.indiatimes.com\/tag\/solid+tumours\" rel=\"nofollow noopener\" target=\"_blank\">solid tumours<\/a>, the Chinese drugmaker said on Thursday.<\/p>\n<p>Shares in Hong-Kong-listed \u200cHUTCHMED were \u2060up \u2060about 15% after the announcement.<\/p>\n<p>Clinical development for <a id=\"38923534\" type=\"Denny\" weightage=\"20\" keywordseo=\"HMPL-A830\" source=\"keywords\" class=\"news-keywords\" href=\"https:\/\/pharma.economictimes.indiatimes.com\/tag\/hmpl-a830\" rel=\"nofollow noopener\" target=\"_blank\">HMPL-A830<\/a> will focus initially on &#8220;colorectal, pancreatic and lung cancer indications&#8221;, HUTCHMED said in a filing to the Hong Kong stock exchange.<\/p>\n<p>A two-part clinical trial \u200bfor HMPL-A830 in China will study \u2060the drug \u200cin patients with solid tumours, \u200brecords \u200bon U.S. government registry ClinicalTrials.gov showed.<\/p>\n<p>Solid \u2060tumours are masses of tissue that can \u200bbe cancer.<\/p>\n<p>The HUTCHMED subsidiary, HUTCHMED \u200bLtd, is also eligible to receive additional payments tied to development, regulatory and commercial milestones of up to about $1.2 billion.<\/p>\n<p>GlaxoSmithKline Intellectual Property (No. 4) Ltd will receive rights to develop and commercialise \u200cHMPL-A830 outside Mainland China, Hong Kong, Macau and Taiwan.<\/p>\n<p>A Phase I development \u200bprogramme for \u200bHMPL-A830 is expected to \u2060start in the second half of 2026, HUTCHMED said.<\/p>\n<p>Asked what specific diseases the Phase I \u200btrials will target and in what countries they will take place, a HUTCHMED spokesperson referred Reuters to its statement and the ClinicalTrials.gov record.<\/p>\n<p>(Reporting by Andrew Silver in Shanghai, additional reporting from Jasmeen Ara Shaikh in Bengaluru; Editing by Subhranshu Sahu)                    <\/p>\n<p>                                    Published On Sep 4, 2026 at 08:17 AM IST<\/p>\n<p>\n                Join the community of 2M+ industry professionals.<br \/>\n                Subscribe to Newsletter to get latest insights &amp; analysis in your inbox.\n            <\/p>\n<p>                    All about ETPharma industry right on your smartphone! <\/p>\n<p>                        <img decoding=\"async\" loading=\"lazy\" width=\"90\" height=\"90\" src=\"https:\/\/www.europesays.com\/britain\/wp-content\/uploads\/2026\/09\/1788532341_735_pharma_barcode.png\" alt=\"\"\/>                        <\/p>\n","protected":false},"excerpt":{"rendered":"Shanghai: GSK subsidiary GlaxoSmithKline Intellectual Property (No. 4) Ltd will pay a unit of HUTCHMED (China) $110 million&hellip;\n","protected":false},"author":2,"featured_media":117655,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[20784],"tags":[48026,25307,20785,47932,48025,48027],"class_list":["post-117654","post","type-post","status-publish","format-standard","has-post-thumbnail","category-gsk","tag-experimental-solid-tumour-drug","tag-glaxosmithkline","tag-gsk","tag-hmpl-a830","tag-hutchmed-licensing-deal","tag-solid-tumours"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@UnitedKingdom\/117213262354322400","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts\/117654","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/comments?post=117654"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts\/117654\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/media\/117655"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/media?parent=117654"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/categories?post=117654"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/tags?post=117654"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}